selected publications
-
Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy.
Proceedings of the National Academy of Sciences of the United States of America.
2020
Academic Article
GET IT
Times cited: 15 -
Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2020
Academic Article
GET IT
Times cited: 113 -
Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art.
Radiology.
2019
Information Resource
GET IT
Times cited: 11 -
Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients.
Molecular pharmaceutics.
2019
Academic Article
GET IT
Times cited: 27 -
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial.
European journal of cancer.
2019
Academic Article
GET IT
Times cited: 44 -
Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2019
Academic Article
GET IT
Times cited: 39 -
Assessment of Simplified Methods for Quantification of 18F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2019
Academic Article
GET IT
Times cited: 11 -
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
JAMA oncology.
2018
Academic Article
GET IT
Times cited: 188 -
Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
JAMA oncology.
2018
Academic Article
GET IT
Times cited: 85 -
Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.
The Prostate.
2018
Information Resource
GET IT
Times cited: 23 -
Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial.
JAMA oncology.
2018
Academic Article
GET IT
Times cited: 46 -
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2018
Academic Article
GET IT
Times cited: 64 -
Reproducibility and Repeatability of Semiquantitative 18F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2018
Academic Article
GET IT
Times cited: 22 -
Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer.
JAMA oncology.
2018
Academic Article
GET IT
Times cited: 90 -
Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire?.
Cancer.
2018
Information Resource
GET IT
Times cited: 41 -
Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.
The oncologist.
2017
Academic Article
GET IT
Times cited: 64 -
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
European urology.
2017
Conference Paper
GET IT
Times cited: 307 -
Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS.
Journal of pharmaceutical and biomedical analysis.
2017
Academic Article
GET IT
Times cited: 32 -
A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer.
Urology.
2016
Academic Article
GET IT
Times cited: 50 -
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2016
Academic Article
GET IT
Times cited: 591 -
Meeting Report From the Prostate Cancer Foundation Scientific Working Group on Radium-223.
The Prostate.
2016
Information Resource
GET IT
Times cited: 3 -
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.
Urologic oncology.
2016
Academic Article
GET IT
Times cited: 48 -
Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2016
Academic Article
GET IT
Times cited: 12 -
Molecular Imaging and Targeted Radionuclide Therapy of Prostate Cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2016
Article
GET IT
Times cited: 8 -
Prostate-Specific Membrane Antigen-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer.
Cancer journal (Sudbury, Mass.).
2016
Information Resource
GET IT
Times cited: 15 -
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2016
Academic Article
GET IT
Times cited: 108 -
A Preanalytic Validation Study of Automated Bone Scan Index: Effect on Accuracy and Reproducibility Due to the Procedural Variabilities in Bone Scan Image Acquisition.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2016
Academic Article
GET IT
Times cited: 25 -
Repeatability of Quantitative 18F-NaF PET: A Multicenter Study.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2016
Academic Article
GET IT
Times cited: 57 -
Fully automated synthesis of [(18) F]fluoro-dihydrotestosterone ([(18) F]FDHT) using the FlexLab module.
Journal of labelled compounds & radiopharmaceuticals.
2016
Academic Article
GET IT
Times cited: 12 -
Radium-223 outcomes after multiple lines of metastatic castration-resistant prostate cancer therapy in clinical practice: implication of pre-treatment spinal epidural disease.
Prostate cancer and prostatic diseases.
2016
Academic Article
GET IT
Times cited: 3 -
Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide.
EJNMMI research.
2016
Academic Article
GET IT
Times cited: 38 -
Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2016
Academic Article
GET IT
Times cited: 24 -
Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
2016
Academic Article
GET IT
Times cited: 18 -
A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance).
EBioMedicine.
2015
Academic Article
GET IT
Times cited: 15 -
Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2015
Academic Article
GET IT
Times cited: 43 - Reply to K. Lu. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Article GET IT
-
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
Cancer.
2015
Academic Article
GET IT
Times cited: 28 -
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2015
Academic Article
GET IT
Times cited: 165 -
Integrative clinical genomics of advanced prostate cancer.
Cell.
2015
Academic Article
GET IT
Times cited: 2513 -
Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors.
EJNMMI research.
2015
Academic Article
GET IT
Times cited: 63 -
Targeting the androgen receptor in prostate and breast cancer: several new agents in development.
Endocrine-related cancer.
2015
Information Resource
GET IT
Times cited: 82 -
Failure of ELM-PC 5: an ineffective drug or an unfit end point?.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2015
Editorial Article
GET IT
Times cited: 5 -
Response.
Radiology.
2015
Article
GET IT
Times cited: 2 -
Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2015
Academic Article
GET IT
Times cited: 118 -
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
Urologic oncology.
2014
Academic Article
GET IT
Times cited: 46 -
Organoid cultures derived from patients with advanced prostate cancer.
Cell.
2014
Academic Article
GET IT
Times cited: 1152 -
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.
European journal of nuclear medicine and molecular imaging.
2014
Academic Article
GET IT
Times cited: 128 -
Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancer.
Health physics.
2014
Academic Article
GET IT
Times cited: 56 -
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2014
Academic Article
GET IT
Times cited: 211 -
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2014
Academic Article
GET IT
Times cited: 387 -
Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival.
Radiology.
2013
Academic Article
GET IT
Times cited: 83 -
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
The Lancet. Oncology.
2013
Academic Article
GET IT
Times cited: 202 -
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).
Cancer.
2013
Academic Article
GET IT
Times cited: 17 -
Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.
Cancer.
2013
Academic Article
GET IT
Times cited: 23 -
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2013
Academic Article
GET IT
Times cited: 355 -
Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.
European journal of nuclear medicine and molecular imaging.
2013
Academic Article
GET IT
Times cited: 153 -
Validation and clinical utility of prostate cancer biomarkers.
Nature reviews. Clinical oncology.
2013
Information Resource
GET IT
Times cited: 70 -
Brain metastases from prostate cancer: an 11-year analysis in the MRI era with emphasis on imaging characteristics, incidence, and prognosis.
Journal of neuroimaging : official journal of the American Society of Neuroimaging.
2012
Academic Article
GET IT
Times cited: 73 -
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer.
Annals of oncology : official journal of the European Society for Medical Oncology.
2012
Academic Article
GET IT
Times cited: 30 -
Computer-aided quantitative bone scan assessment of prostate cancer treatment response.
Nuclear medicine communications.
2012
Academic Article
GET IT
Times cited: 42 -
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2012
Academic Article
GET IT
Times cited: 385 -
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.
European urology.
2012
Academic Article
GET IT
Times cited: 155 -
Augmenting advance care planning in poor prognosis cancer with a video decision aid: a preintervention-postintervention study.
Cancer.
2012
Academic Article
GET IT
Times cited: 72 -
Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2012
Academic Article
GET IT
Times cited: 148 -
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.
Cancer chemotherapy and pharmacology.
2011
Academic Article
GET IT
Times cited: 31 -
Androgen deprivation and thromboembolic events in men with prostate cancer.
Cancer.
2011
Academic Article
GET IT
Times cited: 72 -
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial.
Cancer chemotherapy and pharmacology.
2011
Academic Article
GET IT
Times cited: 21 -
Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2011
Academic Article
GET IT
Times cited: 39 -
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2011
Information Resource
GET IT
Times cited: 193 -
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.
Urologic oncology.
2011
Academic Article
GET IT
Times cited: 53 -
Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer.
BJU international.
2011
Academic Article
GET IT
Times cited: 41 -
Developing imaging strategies for castration resistant prostate cancer.
Acta oncologica (Stockholm, Sweden).
2011
Academic Article
GET IT
Times cited: 41 -
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2010
Academic Article
GET IT
Times cited: 39 -
Methylphenidate for fatigue in ambulatory men with prostate cancer.
Cancer.
2010
Academic Article
GET IT
Times cited: 62 -
Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2010
Academic Article
GET IT
Times cited: 109 -
Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer.
PloS one.
2010
Academic Article
GET IT
Times cited: 15 -
Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer.
Annals of internal medicine.
2010
Academic Article
GET IT
Times cited: 44 -
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.
Lancet (London, England).
2010
Academic Article
GET IT
Times cited: 962 -
Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2010
Academic Article
GET IT
Times cited: 243 -
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2010
Academic Article
GET IT
Times cited: 382 -
Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2010
Academic Article
GET IT
Times cited: 105 -
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2009
Academic Article
GET IT
Times cited: 194 -
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2009
Academic Article
GET IT
Times cited: 84 -
Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer.
European urology.
2009
Academic Article
GET IT
Times cited: 73 -
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.
Clinical genitourinary cancer.
2009
Academic Article
GET IT
Times cited: 21 -
Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer.
British journal of cancer.
2008
Academic Article
GET IT
Times cited: 12 -
Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel.
Cancer.
2008
Academic Article
GET IT
Times cited: 19 -
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2008
Academic Article
GET IT
Times cited: 23 -
Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2008
Academic Article
GET IT
Times cited: 71 -
Expression of prostate-specific membrane antigen in renal cortical tumors.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
2008
Academic Article
GET IT
Times cited: 18 - Editorial Comment. Journal of Urology. 2008 Article GET IT
-
A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.
The Journal of urology.
2007
Academic Article
GET IT
Times cited: 34 -
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2007
Academic Article
GET IT
Times cited: 74 -
Castration resistant, taxane naïve metastatic prostate cancer: current clinical approaches and future directions.
The Journal of urology.
2007
Academic Article
GET IT
Times cited: 6 -
A polyvalent vaccine for high-risk prostate patients: "are more antigens better?".
Cancer immunology, immunotherapy : CII.
2007
Academic Article
GET IT
Times cited: 57 -
Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2007
Academic Article
GET IT
Times cited: 63 -
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2007
Academic Article
GET IT
Times cited: 195 -
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2007
Academic Article
GET IT
Times cited: 87 -
Rapid androgen cycling as treatment for patients with prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2006
Academic Article
GET IT
Times cited: 17 -
Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials.
Nature clinical practice. Oncology.
2006
Information Resource
GET IT
Times cited: 51 - Paclitaxel and carboplatin versus mitoxantrone: lessons of an underpowered study. Nature clinical practice. Oncology. 2006 Academic Article GET IT
-
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2005
Academic Article
GET IT
Times cited: 103 -
Androgen deprivation for minimal metastatic disease: threshold for achieving undetectable prostate-specific antigen.
Urology.
2005
Academic Article
GET IT
Times cited: 7 -
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2005
Academic Article
GET IT
Times cited: 110 -
Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer.
Applied immunohistochemistry & molecular morphology : AIMM.
2005
Academic Article
GET IT
Times cited: 22 -
Imaging therapeutic response in human bone marrow using rapid whole-body MRI.
Magnetic resonance in medicine.
2004
Academic Article
GET IT
Times cited: 63 -
PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2004
Academic Article
GET IT
Times cited: 70 -
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.
Cancer.
2004
Academic Article
GET IT
Times cited: 29 - Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer. Current oncology reports. 2004 Information Resource GET IT
-
Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2004
Academic Article
GET IT
Times cited: 271 -
Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.
Cancer.
2003
Academic Article
GET IT
Times cited: 32 -
Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration.
Annals of oncology : official journal of the European Society for Medical Oncology.
2003
Academic Article
GET IT
Times cited: 58 -
Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer.
Urology.
2002
Academic Article
GET IT
Times cited: 168 -
Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2002
Academic Article
GET IT
Times cited: 173 -
HER-2 profiling and targeting in prostate carcinoma.
Cancer.
2002
Academic Article
GET IT
Times cited: 121 -
HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2001
Academic Article
GET IT
Times cited: 140